Symbol       Canada   US  

Company Profile

IntelliPharmaCeutics International Inc.
Symbol: TSX: IPCI    
Address: 30 Worcester Road
Toronto, Ontario, Canada M9W 5X2
Phone: (416) 798-3001
Fax: (416) 798-3007
Contact: Isa Odidi, CEO
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which received final FDA approval) and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.
Intellipharmaceutics also has NDA 505(b)(2) product candidates in its development pipeline. These include Rexista™ oxycodone, an abuse-deterrent oxycodone based on its proprietary nPODDDS™ and PODRAS™ Paradoxical Overdose Resistance Activating System, and Regabatin™ XR pregabalin extended-release capsules.

People also search for:
Drug Development Stocks
Pharmaceuticals Stocks
Medical Diagnostics and Research Stocks
Financial Results
 Current Quarter
May 31 - 2Q
Year Ago Quarter
May 31 - 2Q
Revenue (000s) 2,002 US$ 556 US$
Net Income (000s) (1,805) US$ (2,000) US$
EPS (0.06) US$ (0.08) US$
 Current 6 monthsYear Ago 6 months
Revenue (000s) 3,237 US$ 1,123 US$
Net Income (000s) (3,796) US$ (4,120) US$
EPS (0.13) US$ (0.17) US$

Live Discussion of IPCI

Search by Symbol       Canada   US